Justin Stebbing

Dr. Justin Stebbing is Editor-in-Chief of Oncogene and a member of the American Society for Clinical Investigation. He has published over 700 papers and during the Covid-19 pandemic his work starting with artificial intelligence led to an FDA EUA for baricitinib, now a fully approved rheumatoid arthritis treatment.

Dr. Stebbing has combined his medical career with healthcare investing. He has worked with Atticus capital, Lansdowne, and Vitruvian partners, and previously chaired the board of BB Healthcare Trust.

Prior to a residency at The Johns Hopkins Hospital, Dr. Stebbing originally gained a first-class medical degree from Trinity College Oxford. He is a Visiting Professor of Cancer Medicine at Imperial, London, having previously been the first NIHR Research Translational Oncology Professor in the UK, and a Professor of Biomedical Sciences at ARU, Cambridge.